DBVT - DBV Technologies' phase 3 trial for peanut allergy treatment in toddlers meets main goal

U.S.-listed shares of DBV Technologies (NASDAQ:DBVT) soared nearly 40% to $2.14 in Tuesday aftermarket trading, after the company said its phase 3 trial assessing its Viaskin Peanut for the treatment of peanut allergies in toddlers aged 1 to 3 years met its main goal. Viaskin Peanut, based on the company's Viaskin technology platform, showed a statistically significant treatment effect, with 67% of the subjects treated with Viaskin Peanut 250 µg meeting response criteria vs. only 33.5% of subjects in the placebo arm. The safety results from the late stage trial - called EPITOPE - were also consistent with the safety profile of Viaskin Peanut observed in children aged 4 years and older with peanut allergy. "DBV intends to further analyze the data from EPITOPE and explore regulatory pathways for Viaskin Peanut in children ages 1 to 3 years, given the high unmet need and absence of approved treatments for this vulnerable population,"

For further details see:

DBV Technologies' phase 3 trial for peanut allergy treatment in toddlers meets main goal